China Medical System Holdings Limited (HKG:0867)

Market Cap	24.11B -24.6%
Revenue (ttm)	10.06B +10.8%
Net Income	1.77B -7.1%
EPS	0.73 -7.2%
Shares Out	2.43B
PE Ratio	13.54
Forward PE	9.46
Dividend	0.34 (3.44%)
Ex-Dividend Date	Aug 28, 2026

Volume	6,197,047
Open	9.84
Previous Close	9.85
Day's Range	9.80 - 10.00
52-Week Range	9.51 - 15.52
Beta	1.09
Analysts	Strong Buy
Price Target	17.67 (+78.31%)
Est. Earnings	Nov 18, 2026

About HKG:0867

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 6,415
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0867

Financial Performance

In 2025, HKG:0867's revenue was 8.21 billion, an increase of 9.95% compared to the previous year's 7.47 billion. Earnings were 1.49 billion, a decrease of -8.08%.

Financial numbers in CNY

Analyst Summary

According to 10 analysts, the average rating for 0867 stock is "Strong Buy." The 12-month stock price target is $17.67, which is an increase of 78.31% from the latest price.

Price Target

$17.67

(78.31% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 29, 2026

Data Sources Report a data error